The Hereditary Angioedema Market is expected to register a CAGR of 9.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Hereditary Angioedema Market report covers segmental analysis by Drugs (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, Others); Route of Administration (Subcutaneous, Intravenous, Oral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Hereditary Angioedema Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Hereditary Angioedema Market Segmentation
Drugs- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Bradykinin Receptor
- Attenuated Androgens
- Subcutaneous
- Intravenous
- Oral
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Strategic Insights
Hereditary Angioedema Market Growth Drivers- Increasing Patient Pool and Prevalence: The prevalence of Hereditary Angioedema is relatively rare but significant enough to drive market growth. With better reporting systems, improved genetic screening, and more sophisticated healthcare infrastructure, the identification of HAE cases is becoming more prevalent globally. This growing patient pool increases the demand for treatment options, further driving the market for HAE-related therapies.
- Increased Research and Clinical Trials: The increasing number of research studies and clinical trials focused on Hereditary Angioedema plays a vital role in developing new treatment options and improving existing ones. These studies are essential for understanding the genetic and molecular basis of HAE, providing insights that can lead to more effective therapies. Furthermore, as the number of clinical trials grows, it increases the availability of treatments, which in turn fuels market growth.
- Growing Patient Advocacy and Support Groups: The rise in patient advocacy groups and support organizations dedicated to Hereditary Angioedema is helping to raise awareness about the condition. These groups are instrumental in providing resources, and emotional support, and promoting research for better treatments. By empowering patients and their families, these organizations also help drive demand for better therapies, thus positively influencing the HAE market.
- Focus on Preventive and Long-Term Care: In the future, there will be a growing emphasis on preventive care and long-term management of Hereditary Angioedema. With better treatment options becoming available, healthcare systems are focusing more on preventing HAE attacks and reducing the frequency of episodes. This trend could involve early intervention strategies, lifestyle modifications, and continuous monitoring of patients' condition, helping to reduce healthcare costs and improve quality of life. The market for preventive treatments and ongoing care solutions is expected to expand as these strategies become more widely adopted.
- Development of Oral and Non-Injection-Based Therapies: As patient preferences shift toward more convenient and less invasive treatments, the Hereditary Angioedema market is likely to see the development of oral and non-injection-based therapies. Oral medications that can manage HAE attacks or prevent them from occurring would be highly beneficial for patients, reducing the need for frequent injections and hospital visits. This trend would appeal to patients seeking greater convenience, and as pharmaceutical companies continue to innovate, these treatments could become a major segment of the HAE market.
- Telemedicine and Remote Monitoring for HAE Management: Telemedicine and remote patient monitoring are increasingly becoming integral components of healthcare delivery, particularly for chronic and rare diseases like Hereditary Angioedema. Remote consultations, virtual care platforms, and digital health tools allow healthcare providers to closely monitor patients' symptoms, adjust treatment plans, and provide timely interventions. This trend will enhance patient convenience, reduce hospital visits, and increase treatment adherence, all of which will likely drive the growth of the HAE market in the coming years.
- Home-Based and Self-Administered Treatments: There is growing demand for home-based and self-administered treatments in the Hereditary Angioedema market. Many patients prefer the convenience and comfort of receiving treatments at home rather than frequent hospital visits. The opportunity lies in the development of easy-to-use, injectable, and subcutaneous therapies that patients can administer themselves. Pharmaceutical companies have the chance to capitalize on this trend by developing patient-friendly solutions that provide more independence and improve the quality of life for HAE sufferers, further expanding their market reach.
- Growing Demand for Early Diagnosis and Screening: The opportunity for market expansion lies in improving early diagnosis and screening for Hereditary Angioedema. Increased awareness about the condition, coupled with advancements in genetic screening technologies, provides opportunities for diagnostic companies to offer innovative screening solutions that detect HAE earlier in at-risk populations. Early diagnosis allows for better management of the disease, ultimately leading to better treatment outcomes. Companies involved in diagnostic tools and services have significant growth potential in this area as HAE awareness continues to increase globally.
- Increased Focus on Patient Advocacy and Education: Patient advocacy groups and educational initiatives are critical to raising awareness about Hereditary Angioedema. As more patients and healthcare providers become informed about HAE, the demand for comprehensive patient support programs, educational resources, and advocacy initiatives is expected to grow. This presents opportunities for pharmaceutical companies, healthcare organizations, and NGOs to collaborate and create more targeted educational campaigns. By investing in patient education and support, stakeholders can enhance the patient experience and foster brand loyalty in the HAE market.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Hereditary Angioedema Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Hereditary Angioedema Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Hereditary Angioedema Market is expected to register a CAGR of 9,5% from 2025-2031.
The major factors impacting the Hereditary Angioedema Market are: Increasing Patient Pool and Prevalence, Increased Research and Clinical Trials and Growing Patient Advocacy and Support Groups
Key future trends in this market are - Focus on Preventive and Long-Term Care, Development of Oral and Non-Injection-Based Therapies and Telemedicine and Remote Monitoring for HAE Management
Key companies of this market are: BIOCRYST PHARMACEUTICALS, INC, CSL, Ionis Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, Pharming Group N.V., Sanofi N.V., Shire plc., Teva Pharmaceutical Industries, Ltd., Attune Pharmaceuticals and KalVista Pharmaceuticals, Inc
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Hereditary Angioedema Market - By Drugs
1.3.2 Hereditary Angioedema Market - By Route of Administration
1.3.3 Hereditary Angioedema Market - By Distribution Channel
1.3.4 Hereditary Angioedema Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. HEREDITARY ANGIOEDEMA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. HEREDITARY ANGIOEDEMA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. HEREDITARY ANGIOEDEMA MARKET - GLOBAL MARKET ANALYSIS
6.1. HEREDITARY ANGIOEDEMA - GLOBAL MARKET OVERVIEW
6.2. HEREDITARY ANGIOEDEMA - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. HEREDITARY ANGIOEDEMA MARKET - REVENUE AND FORECASTS TO 2028 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. C1 ESTERASE INHIBITOR
7.3.1. Overview
7.3.2. C1 Esterase Inhibitor Market Forecast and Analysis
7.4. KALLIKREIN INHIBITOR
7.4.1. Overview
7.4.2. Kallikrein Inhibitor Market Forecast and Analysis
7.5. BRADYKININ RECEPTOR
7.5.1. Overview
7.5.2. Bradykinin Receptor Market Forecast and Analysis
7.6. ATTENUATED ANDROGENS
7.6.1. Overview
7.6.2. Attenuated Androgens Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. HEREDITARY ANGIOEDEMA MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. SUBCUTANEOUS
8.3.1. Overview
8.3.2. Subcutaneous Market Forecast and Analysis
8.4. INTRAVENOUS
8.4.1. Overview
8.4.2. Intravenous Market Forecast and Analysis
8.5. ORAL
8.5.1. Overview
8.5.2. Oral Market Forecast and Analysis
9. HEREDITARY ANGIOEDEMA MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. E-COMMERCE
9.5.1. Overview
9.5.2. E-Commerce Market Forecast and Analysis
10. HEREDITARY ANGIOEDEMA MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Hereditary Angioedema Market Overview
10.1.2 North America Hereditary Angioedema Market Forecasts and Analysis
10.1.3 North America Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.1.4 North America Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.1.6.1 United States Hereditary Angioedema Market
10.1.6.1.1 United States Hereditary Angioedema Market by Drugs
10.1.6.1.2 United States Hereditary Angioedema Market by Route of Administration
10.1.6.1.3 United States Hereditary Angioedema Market by Distribution Channel
10.1.6.2 Canada Hereditary Angioedema Market
10.1.6.2.1 Canada Hereditary Angioedema Market by Drugs
10.1.6.2.2 Canada Hereditary Angioedema Market by Route of Administration
10.1.6.2.3 Canada Hereditary Angioedema Market by Distribution Channel
10.1.6.3 Mexico Hereditary Angioedema Market
10.1.6.3.1 Mexico Hereditary Angioedema Market by Drugs
10.1.6.3.2 Mexico Hereditary Angioedema Market by Route of Administration
10.1.6.3.3 Mexico Hereditary Angioedema Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Hereditary Angioedema Market Overview
10.2.2 Europe Hereditary Angioedema Market Forecasts and Analysis
10.2.3 Europe Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.2.4 Europe Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Hereditary Angioedema Market
10.2.6.1.1 Germany Hereditary Angioedema Market by Drugs
10.2.6.1.2 Germany Hereditary Angioedema Market by Route of Administration
10.2.6.1.3 Germany Hereditary Angioedema Market by Distribution Channel
10.2.6.2 France Hereditary Angioedema Market
10.2.6.2.1 France Hereditary Angioedema Market by Drugs
10.2.6.2.2 France Hereditary Angioedema Market by Route of Administration
10.2.6.2.3 France Hereditary Angioedema Market by Distribution Channel
10.2.6.3 Italy Hereditary Angioedema Market
10.2.6.3.1 Italy Hereditary Angioedema Market by Drugs
10.2.6.3.2 Italy Hereditary Angioedema Market by Route of Administration
10.2.6.3.3 Italy Hereditary Angioedema Market by Distribution Channel
10.2.6.4 Spain Hereditary Angioedema Market
10.2.6.4.1 Spain Hereditary Angioedema Market by Drugs
10.2.6.4.2 Spain Hereditary Angioedema Market by Route of Administration
10.2.6.4.3 Spain Hereditary Angioedema Market by Distribution Channel
10.2.6.5 United Kingdom Hereditary Angioedema Market
10.2.6.5.1 United Kingdom Hereditary Angioedema Market by Drugs
10.2.6.5.2 United Kingdom Hereditary Angioedema Market by Route of Administration
10.2.6.5.3 United Kingdom Hereditary Angioedema Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Hereditary Angioedema Market Overview
10.3.2 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis
10.3.3 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.3.4 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Hereditary Angioedema Market
10.3.6.1.1 Australia Hereditary Angioedema Market by Drugs
10.3.6.1.2 Australia Hereditary Angioedema Market by Route of Administration
10.3.6.1.3 Australia Hereditary Angioedema Market by Distribution Channel
10.3.6.2 China Hereditary Angioedema Market
10.3.6.2.1 China Hereditary Angioedema Market by Drugs
10.3.6.2.2 China Hereditary Angioedema Market by Route of Administration
10.3.6.2.3 China Hereditary Angioedema Market by Distribution Channel
10.3.6.3 India Hereditary Angioedema Market
10.3.6.3.1 India Hereditary Angioedema Market by Drugs
10.3.6.3.2 India Hereditary Angioedema Market by Route of Administration
10.3.6.3.3 India Hereditary Angioedema Market by Distribution Channel
10.3.6.4 Japan Hereditary Angioedema Market
10.3.6.4.1 Japan Hereditary Angioedema Market by Drugs
10.3.6.4.2 Japan Hereditary Angioedema Market by Route of Administration
10.3.6.4.3 Japan Hereditary Angioedema Market by Distribution Channel
10.3.6.5 South Korea Hereditary Angioedema Market
10.3.6.5.1 South Korea Hereditary Angioedema Market by Drugs
10.3.6.5.2 South Korea Hereditary Angioedema Market by Route of Administration
10.3.6.5.3 South Korea Hereditary Angioedema Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Hereditary Angioedema Market Overview
10.4.2 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis
10.4.3 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.4.4 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Hereditary Angioedema Market
10.4.6.1.1 South Africa Hereditary Angioedema Market by Drugs
10.4.6.1.2 South Africa Hereditary Angioedema Market by Route of Administration
10.4.6.1.3 South Africa Hereditary Angioedema Market by Distribution Channel
10.4.6.2 Saudi Arabia Hereditary Angioedema Market
10.4.6.2.1 Saudi Arabia Hereditary Angioedema Market by Drugs
10.4.6.2.2 Saudi Arabia Hereditary Angioedema Market by Route of Administration
10.4.6.2.3 Saudi Arabia Hereditary Angioedema Market by Distribution Channel
10.4.6.3 U.A.E Hereditary Angioedema Market
10.4.6.3.1 U.A.E Hereditary Angioedema Market by Drugs
10.4.6.3.2 U.A.E Hereditary Angioedema Market by Route of Administration
10.4.6.3.3 U.A.E Hereditary Angioedema Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Hereditary Angioedema Market Overview
10.5.2 South and Central America Hereditary Angioedema Market Forecasts and Analysis
10.5.3 South and Central America Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.5.4 South and Central America Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Hereditary Angioedema Market
10.5.6.1.1 Brazil Hereditary Angioedema Market by Drugs
10.5.6.1.2 Brazil Hereditary Angioedema Market by Route of Administration
10.5.6.1.3 Brazil Hereditary Angioedema Market by Distribution Channel
10.5.6.2 Argentina Hereditary Angioedema Market
10.5.6.2.1 Argentina Hereditary Angioedema Market by Drugs
10.5.6.2.2 Argentina Hereditary Angioedema Market by Route of Administration
10.5.6.2.3 Argentina Hereditary Angioedema Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. HEREDITARY ANGIOEDEMA MARKET, KEY COMPANY PROFILES
12.1. BIOCRYST PHARMACEUTICALS, INC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CSL
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. IONIS PHARMACEUTICALS, INC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. MERCK SHARP AND DOHME CORP
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PHARMING GROUP N.V
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. SANOFI N.V
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SHIRE PLC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. TEVA PHARMACEUTICAL INDUSTRIES, LTD
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ATTUNE PHARMACEUTICALS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. KALVISTA PHARMACEUTICALS, INC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
- BIOCRYST PHARMACEUTICALS, INC
- CSL
- Ionis Pharmaceuticals, Inc.
- Merck Sharp & Dohme Corp
- Pharming Group N. V.
- Sanofi N. V.
- Shire plc.
- Teva Pharmaceutical Industries, Ltd.
- Attune Pharmaceuticals
- KalVista Pharmaceuticals, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For